4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Tinea Capitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 4 ongoing clinical trials involving Tinea Capitis
Of the 4 trials,2 trials are in Phase I
Furthermore, 1 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Tinea Capitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Tinea Capitis, an Infectious disease. The largest number of ongoing clinical trials for Tinea Capitis is conducted in the Middle East and Africa. Asia-Pacific is another prominent region engaged in Tinea Capitis-related drug trials.

Al-Azhar University: The leading ongoing Tinea Capitis related clinical trial sponsor

Al-Azhar University is the top sponsor for Tinea Capitis-related ongoing clinical trials.

Bishen Skin Center is another notable clinical trial sponsor involved in Tinea Capitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Tinea Capitis

Ketoconazole (Nizoral, Nizoral GR, Nizral, Daktarin Gold, Terzolin, Ketoderm, Fungarest, Cetonax, Nizoral A-D, Triatop, Niz, Fungoral), Fenticonazole nitrate (Lomexin, Gynoxin, Terlomexin, Gyno-Lomexin, Lorenil, Credigyne, Falvin, Laurimic, Fentibel), and Miconazole (Florid) are among the key marketed drugs involving Tinea Capitis.

Ketoconazole (Nizoral, Nizoral GR, Nizral, Daktarin Gold, Terzolin, Ketoderm, Fungarest, Cetonax, Nizoral A-D, Triatop, Niz, Fungoral) is an anti-fungal, anti-infective agent. It functions via Lanosterol 14 Alpha Demethylase Inhibitor mechanism of action. It is formulated as gel, solution, lotion, shampoo and cream for topical application and as tablets, granules and suspension for oral route of administration and ovule for vaginal route administration. Ketoconazole is indicated for the treatment of fungal infections, skin infections, dermatophytosis, onychomycosis (tinea unguium), pityriasis simplex capillitii (dandruff), folliculitis, vulvovaginal candidiasis, histoplasmosis. Ketoconazole was first approved in 1980 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Kramer Laboratories Inc, Johnson & Johnson, and Patriot Pharmaceuticals LLC.

Fenticonazole nitrate (Lomexin, Gynoxin, Terlomexin, Gyno-Lomexin, Lorenil, Credigyne, Falvin, Laurimic, Fentibel) is an imidazole derivative that acts as an anti-fungal agent. It functions via Lanosterol 14 Alpha Demethylase Inhibitor mechanism of action. It is formulated as cream, spray, powder, gel,solution,for topical route administration and cream, pessary, soft capsules for vaginal administration. The topical preparations are used for the treatment of dermatomycoses, tinea capitis, tinea corporis, tinea cruris, tinea pedis (athlete's foot), tinea manuum, tinea faciei, tinea barbae, tinea unguium, candidiasis of the skin, pityriasis versicolor, onichia and paronychia. Fenticonazole nitrate was first approved in 1986 and is marketed globally including the UK, Austria, France, Germany, and South Africa by G.L. Pharma GmbH.